Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin's October rally pattern falters as 2025-26 show weaker seasonal gains and caution rises.

Market News
05 Oct 2026
Bitcoin
View Source
Neutral
Bitcoin's October rally pattern falters as 2025-26 show weaker seasonal gains and caution rises.

Bitcoin's historically strong months, especially October and February, have recently failed to deliver expected gains, with losses recorded in 2025 and 2026. While October has traditionally seen a median gain of around 15%, recent years show smaller and less consistent price changes, challenging the popular "Uptober" narrative of a strong October rally. Analysts warn that relying solely on seasonal patterns is risky, as market dynamics and other factors now play a larger role. Investors should be cautious and not depend solely on historic monthly trends for trading decisions.

Bitcoin's recent performance challenges the 'Uptober' hype. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: out of 50 major cryptocurrencies, 24 rose and 25 fell today. Notable movers include CAKE at Rp43.884 with a -2.22% change and a typical hold time of 75 days, FTM at Rp11.382 down 2.05%, and XLM at Rp3.838 down 2.04% with 72% sell order activity.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
Near Protocol (NEAR) jumps nearly 6% amid $280K short liquidations on major exchanges

Near Protocol (NEAR) jumps nearly 6% amid $280K short liquidations on major exchanges

Near Protocol (NEAR) surged to $5.28, rising 5.94% within four hours on October 6, driven by $280,000 worth of short position liquidations across Binance, Bybit, and OKX. The price climbed from $4.98 during this period and showed a 7.14% gain over th...

Market News
Bullish
4 hours ago
Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

A class action lawsuit has been filed against Alphabet Inc. for allegedly making false and misleading statements about the performance and launch delays of its Gemini 3.5 Pro product between May 19 and July 16, 2026. The lawsuit claims these misstate...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App